thymalfasin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2643 | 62304-98-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A thymus hormone polypeptide found in thymosin fraction 5 (a crude thymus gland extract) but now produced by synthesis. It is used alone or with interferon as an immunomodulator for the treatment of CHRONIC HEPATITIS B and HEPATITIS C. Thymalfasin is also used for the treatment of chemotherapy-induced immunosuppression, and to enhance the efficacy of influenza and hepatitis B vaccines in immunocompromised patients.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Off label use | 95.38 | 62.77 | 38 | 84 | 907177 | 78837089 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000276 | Adjuvants, Immunologic |
| MeSH PA | D007155 | Immunologic Factors |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.94 | acidic |
| pKa2 | 3.2 | acidic |
| pKa3 | 3.29 | acidic |
| pKa4 | 3.51 | acidic |
| pKa5 | 3.83 | acidic |
| pKa6 | 3.97 | acidic |
| pKa7 | 4.1 | acidic |
| pKa8 | 4.24 | acidic |
| pKa9 | 4.47 | acidic |
| pKa10 | 4.81 | acidic |
| pKa11 | 12.01 | acidic |
| pKa12 | 12.31 | acidic |
| pKa13 | 12.53 | acidic |
| pKa14 | 12.62 | acidic |
| pKa15 | 12.88 | acidic |
| pKa16 | 12.89 | acidic |
| pKa17 | 13.15 | acidic |
| pKa18 | 13.18 | acidic |
| pKa19 | 13.43 | acidic |
| pKa20 | 13.43 | acidic |
| pKa21 | 13.46 | acidic |
| pKa22 | 13.52 | acidic |
| pKa23 | 13.63 | acidic |
| pKa24 | 13.79 | acidic |
| pKa25 | 13.91 | acidic |
| pKa26 | 13.96 | acidic |
| pKa27 | 13.99 | acidic |
| pKa28 | 11.41 | Basic |
| pKa29 | 10.98 | Basic |
| pKa30 | 10.63 | Basic |
| pKa31 | 10.21 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D06116 | KEGG_DRUG |
| C0076612 | UMLSCUI |
| CHEBI:135915 | CHEBI |
| CHEMBL2103979 | ChEMBL_ID |
| D000077596 | MESH_DESCRIPTOR_UI |
| DB04900 | DRUGBANK_ID |
| 7344 | INN_ID |
| W0B22ISQ1C | UNII |
| 16130571 | PUBCHEM_CID |
| 38221 | RXNORM |
| 009083 | NDDF |
| 421968008 | SNOMEDCT_US |
| 422261006 | SNOMEDCT_US |
Pharmaceutical products:
None